A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Status: Recruiting
Phase: Phase 1/Phase 2
Diagnosis: Lung Cancer
NCT ID: NCT01237678 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:

 

The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center

Overall PI:
Leena Gandhi, MD, PhD, Dana-Farber Cancer Institute

Site-responsible Investigators:
Panagiotis Fidias, MD, Massachusetts General Hospital

Contacts:
Dana-Farber Cancer Institute: Kelly Masone, 617-632-3383, kmasone@partners.org
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Patients must be 18 years old - Patients must have been diagnosed with small-cell lung cancer (SCLC) and extensive disease - ECOG performance status of 0, 1, or 2 - No prior systemic chemotherapy for the treatment of SCLC Exclusion Criteria: - Pregnant or lactating females
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms